三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LABU 三倍做多标普生物-Direxion

盘后交易 10-21 17:38:39 EDT

234.18

-1.81

-0.77%

盘后233.67

-0.51-0.22%

17:27 EDT

最高247.50	最低233.70	成交量31.35万
今开237.60	昨收235.99	日振幅5.85%
总市值6.38亿	流通市值6.38亿	总股本272.45万
成交额7,496万	换手率11.51%	流通股本272.45万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":234.18,"timestamp":1792612800000,"preClose":235.99,"halted":0,"volume":313549,"hourTrading":{"tag":"盘后","latestPrice":233.67,"preClose":234.18,"latestTime":"17:27 EDT","volume":163,"amount":38128.69105,"timestamp":1792618042554,"change":-0.51,"changeRate":-0.002178,"amplitude":0.006832},"delay":0,"changeRate":-0.007669816517649062,"floatShares":2724486,"shares":2724486,"eps":0,"marketStatus":"盘后交易","change":-1.81,"latestTime":"10-21 17:38:39 EDT","open":237.6,"high":247.5,"low":233.7,"amount":74957014.53353,"amplitude":0.058477,"askPrice":234.6,"askSize":50,"bidPrice":233.04,"bidSize":2,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792627200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":235.99,"sharesOutstanding":3024486,"nav":212.88,"aum":569343472.7,"dividendRate":0.00393,"bidAskSpread":0.003001,"preHourTrading":{"tag":"盘前","latestPrice":237.23,"preClose":235.99,"latestTime":"09:26 EDT","volume":1261,"amount":297221.69737,"timestamp":1792589211587,"change":1.24,"changeRate":0.005254,"amplitude":0.031781},"postHourTrading":{"tag":"盘后","latestPrice":233.67,"preClose":234.18,"latestTime":"17:27 EDT","volume":163,"amount":38128.69105,"timestamp":1792618042554,"change":-0.51,"changeRate":-0.002178,"amplitude":0.006832},"volumeRatio":0.740307,"impliedVol":1.0129,"impliedVolPercentile":0.8645},"requestUrl":"/m/hq/s/LABU","defaultTab":"news","newsList":[{"id":"2677670248","title":"全球首款乙肝功能性治愈ASO药物获FDA批准，慢乙肝治疗进入“治愈时代”","url":"https://stock-news.laohu8.com/highlight/detail?id=2677670248","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677670248?lang=zh_cn&edition=full","pubTime":"2026-10-21 22:40","pubTimestamp":1792593600,"startTime":"0","endTime":"0","summary":"随着核酸药物和新型基因表达调控技术不断发展，全球多家生物医药企业正在探索从不同层面干预慢性乙型肝炎病毒持续感染的新策略。过去数十多年里，核苷（酸）类似物一直是慢性乙肝治疗的绝对主流，这类药物能强效抑制乙肝病毒的逆转录过程，快速把血液中的病毒载量降到检测线以下，把大量患者从肝硬化、肝衰竭的边缘拉了回来。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610213903005530.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610213903005530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677567828","title":"2026年前三季度医保统筹基金支出超1.7万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677567828","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677567828?lang=zh_cn&edition=full","pubTime":"2026-10-21 18:54","pubTimestamp":1792580065,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["XBI","XLV","BK4588","BK4585","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677762092","title":"2026年前三季度医保统筹基金支出超1.7万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677762092","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677762092?lang=zh_cn&edition=full","pubTime":"2026-10-21 18:19","pubTimestamp":1792577986,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4581","XBI","BK4585","BK4588","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677175566","title":"奥林巴斯：部分产品收到FDA进口警示。FDA的进口警示不会影响本财年的收益。","url":"https://stock-news.laohu8.com/highlight/detail?id=2677175566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677175566?lang=zh_cn&edition=full","pubTime":"2026-10-21 07:32","pubTimestamp":1792539167,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194477749","title":"异动解读｜三倍做多标普生物-Direxion盘中上涨8.35%，医疗保健板块走强带动生物科技杠杆产品反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1194477749","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194477749?lang=zh_cn&edition=full","pubTime":"2026-10-20 22:36","pubTimestamp":1792507007,"startTime":"0","endTime":"0","summary":"10月20日，三倍做多标普生物-Direxion盘中上涨8.35%，报230.8美元，成交额3546.82万美元。消息面上，公开信息显示，医疗保健板块走强带动生物科技杠杆产品反弹，是本次异动的直接催化。从背景看，标普生物科技精选行业指数此前已出现反弹，相关产品对板块波动高度敏感；作为三倍杠杆工具，该产品在风险偏好回升阶段通常会放大生物科技板块涨幅，此前同类异动中亦曾出现超8%的单日波动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"医疗保健走强，三倍做多生物科技反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676668617","title":"健友股份(603707.SH)子公司产品甲磺酸艾立布林注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2676668617","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676668617?lang=zh_cn&edition=full","pubTime":"2026-10-20 15:46","pubTimestamp":1792482360,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司子公司健进制药有限公司于近日收到美国食品药品监督管理局(简称“美国FDA”)签发的甲磺酸艾立布林注射液(1mg/2mL)的ANDA批准通知。该药品适用于既往已接受过至少两种化疗方案治疗的转移性乳腺癌患者，以及既往接受过含蒽环类药物治疗方案的不可切除或转移性脂肪肉瘤患者。新批准产品进一步丰富了公司国际化的产品管线，强化公司国际市场布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0186","BK4585","LABU","BK4588","603707","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676166853","title":"健友股份：子公司甲磺酸艾立布林注射液1mg/2mL获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2676166853","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676166853?lang=zh_cn&edition=full","pubTime":"2026-10-20 15:43","pubTimestamp":1792482203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676365597","title":"港股异动 | 药明生物(02269)早盘涨近7% 无锡马山基地顺利通过美国FDA GMP现场核查","url":"https://stock-news.laohu8.com/highlight/detail?id=2676365597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676365597?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:10","pubTimestamp":1792465807,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药明生物早盘涨近7%。消息面上，药明生物近期宣布，无锡马山基地顺利通过美国FDA未预先通知的GMP现场核查，本次核查无重大、关键缺陷，顺利关厂。核查覆盖基地多款已在美国获批上市的生物药品种全生产体系，公司质量管控体系再次获得全球最高药监标准认可。公开资料显示，药明生物无锡马山基地是中国首个获得FDA和EMA批准进行商业化生产的生物制药基地，也是公司原液与制剂协同运营的重要生产基地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1794554557.SGD","LU0327786744.USD","BK1521","BK4588","LU0029874061.USD","LU1880383366.USD","LU0823426308.USD","LU2039709279.SGD","BK1589","LU0516423174.USD","BK1141","BK1576","LU0043850808.USD","LU1961090484.USD","LU0856984785.SGD","LU0516422952.EUR","LU0819121731.USD","LU0516423091.SGD","LU0348825331.USD","BK1610","LU1242518857.USD","KCAI","LU0348735423.USD","LU0359201612.USD","LU1242518931.SGD","LU0588546209.SGD","LU0708995583.HKD","LU2476274720.SGD","LU0572944931.SGD","SG9999002562.SGD","LU0540923850.HKD","LU0307460666.USD","IE00B0JY6N72.USD","LU0417516738.SGD","VXUS","02269","LU0561508036.HKD","LABU","KURE","LU0128526141.USD","LU0708995153.HKD","LU0516422366.SGD","LU0140636845.USD","LU0823426480.USD","SG9999002463.SGD","LU0029874905.USD","LU0181495838.USD","LU0634319403.HKD","LU0979878070.USD","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676187653","title":"礼邦医药-B早盘一度飙升逾47% AP308获FDA临床许可及国内受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2676187653","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676187653?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:22","pubTimestamp":1792462920,"startTime":"0","endTime":"0","summary":"模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。礼邦医药-B早盘一度飙升逾47%。截至发稿，股价回落现涨11.04%，报19.41港元，成交额8187.61万港元。北大医院近日宣布，其肾脏内科与礼邦医药联合开发的新一代AP308/PKU308用于治疗IgA肾病的新药临床试验申请获美国FDA批准，即将进入首次人体临床研究阶段。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-20/doc-inivvsvt5849002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","LABU","BK1191","BK4585","09939","159938","BK1161","BK1574","09637","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197425058","title":"异动解读｜三倍做多标普生物-Direxion盘中上涨8.16%，医疗保健板块走强带动生物科技杠杆产品反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1197425058","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197425058?lang=zh_cn&edition=full","pubTime":"2026-10-20 01:30","pubTimestamp":1792431046,"startTime":"0","endTime":"0","summary":"10月20日，三倍做多标普生物-Direxion盘中上涨8.16%，报215.0美元，成交额7199.77万美元。消息面上，最新公开信息显示，医疗保健板块走强带动生物科技杠杆产品反弹。此前同类产品曾在板块回撤时盘中下跌8.28%，反映出三倍杠杆工具对生物科技板块波动高度敏感；在医疗保健与生物科技风险偏好回升时，其涨幅通常也会被同步放大。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"医疗保健走强，三倍做多标普生物盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676394506","title":"ST人福(600079.SH)：芦比前列酮软胶囊获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2676394506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676394506?lang=zh_cn&edition=full","pubTime":"2026-10-19 15:49","pubTimestamp":1792396152,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST人福(600079.SH)发布公告，公司全资子公司人福普克药业(武汉)有限公司(简称“人福普克”)近日收到美国食品药品监督管理局(FDA)关于芦比前列酮软胶囊的批准文号。芦比前列酮软胶囊被批准用于治疗：(1)成人慢性特发性便秘(CIC);(2)用于伴有慢性非癌性疼痛的成人患者的阿片类药物诱导便秘(OIC)，包括既往罹患癌症或癌症治疗相关慢性疼痛、且无需频繁(如每周)上调阿片类药物剂量的患者;(3)用于18岁及以上女性便秘型肠易激综合征(IBS‑C)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0012","BK0028","600079","BK0185","BK0239","LABU","BK0070","BK0096","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676450684","title":"ST人福：芦比前列酮软胶囊获美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2676450684","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676450684?lang=zh_cn&edition=full","pubTime":"2026-10-19 15:45","pubTimestamp":1792395925,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175958162","title":"异动解读｜三倍做多标普生物-Direxion盘中下跌8.28%，前期反弹后生物科技杠杆产品回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1175958162","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175958162?lang=zh_cn&edition=full","pubTime":"2026-10-16 23:16","pubTimestamp":1792163815,"startTime":"0","endTime":"0","summary":"10月16日，三倍做多标普生物-Direxion盘中下跌8.28%，报204.48美元，成交额3873.54万美元。消息面上，此前医疗保健板块整体走强曾带动生物科技相关ETF同步上行，杠杆产品涨幅被放大；但该类产品对板块波动高度敏感，在前一交易时段大涨后，盘中出现明显回落。此前NYSE Healthcare Index一度上涨2.3%，XLV上涨2.4%，iShares Biotechnology ETF上涨2.5%，个股层面Adlai Nortye与Verastem的强势表现曾提振风险偏好。作为三倍做多生物科技产品，LABU在板块回撤时跌幅亦会被放大。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技杠杆产品异动，三倍做多回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675003594","title":"FDA批准非处方滴眼液Brytly，用于缓解轻微刺激引起的眼部发红。","url":"https://stock-news.laohu8.com/highlight/detail?id=2675003594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675003594?lang=zh_cn&edition=full","pubTime":"2026-10-16 20:36","pubTimestamp":1792154189,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675059407","title":"FDA批准一款用于缓解眼红的新非处方眼药水。","url":"https://stock-news.laohu8.com/highlight/detail?id=2675059407","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675059407?lang=zh_cn&edition=full","pubTime":"2026-10-16 20:35","pubTimestamp":1792154134,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675595420","title":"罗氏（RHHBY）重磅药Enspryng获FDA批准新适应症 成首个甲状腺眼病皮下注射疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2675595420","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675595420?lang=zh_cn&edition=full","pubTime":"2026-10-16 18:22","pubTimestamp":1792146163,"startTime":"0","endTime":"0","summary":"金吾财讯 | 罗氏 宣布，美国食品药品监督管理局已批准其白介素-6受体抑制剂Enspryng用于治疗成人甲状腺眼病。这标志着该药获得的第二个适应症，也是目前首个且唯一用于TED的居家皮下注射疗法，维持期给药频率为每四周一次。据介绍，此次批准主要基于关键III期SatraGO系列临床试验的数据。其中，SatraGO-2研究显示，在活动性TED患者群中，Enspryng治疗组在眼球突出改善率和复视减轻率上均显著优于对照组。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NTI5YTQ1ZTkxNTlmNGI5OWJmMmI4NWFlNDQwMzZkYjU0MjU3NDEwNjkw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTI5YTQ1ZTkxNTlmNGI5OWJmMmI4NWFlNDQwMzZkYjU0MjU3NDEwNjkw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"307288","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4588","LABU","03165","BK4585","RHHBY","HRTS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675552723","title":"和黄医药盘中涨超5%，联合疗法FDA上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2675552723","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675552723?lang=zh_cn&edition=full","pubTime":"2026-10-16 10:20","pubTimestamp":1792117200,"startTime":"0","endTime":"0","summary":"10月16日，和黄医药(00013.HK)盘中涨超5%，截至10时8分，涨5.13%，报22.58港元/股，成交额4623.56万港元。消息面上，今年以来我国创新药对外授权交易总额已突破1200亿美元、同比增长36%，首 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261016/c680763629.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261016/c680763629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["IPOS","BK1191","LABU","00013","BK4585","BK1587","BK4588","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121652343","title":"异动解读｜三倍做多标普生物-Direxion盘中上涨8.12%，医疗保健板块走强带动生物科技杠杆产品反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1121652343","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121652343?lang=zh_cn&edition=full","pubTime":"2026-10-16 03:42","pubTimestamp":1792093375,"startTime":"0","endTime":"0","summary":"10月16日，三倍做多标普生物-Direxion盘中上涨8.12%，报227.07美元，成交额8484.12万美元。消息面上，医疗保健板块当日下午整体走强，带动生物科技相关ETF同步上行，放大了杠杆产品涨幅。当日NYSE Healthcare Index上涨2.3%，XLV上涨2.4%，iShares Biotechnology ETF上涨2.5%。个股层面，Adlai Nortye因与礼来及默克KGaA签署临床合作与供药协议涨近8%，Verastem获RBC上调目标价后涨逾25%，共同提振生物科技风险偏好。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"医疗板块走强，三倍做多生物科技拉升","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675009347","title":"美国卫生部长表示，CMS在2026年发现18.9万例重复的联邦医疗保险、医疗补助或儿童健康保险计划覆盖案例。","url":"https://stock-news.laohu8.com/highlight/detail?id=2675009347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675009347?lang=zh_cn&edition=full","pubTime":"2026-10-14 21:42","pubTimestamp":1791985326,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999014005.SGD","XBI","LU0266013472.USD","LU0238689110.USD","LU0211331839.USD","XHS","LU1093756168.USD","RSPH","FXH","LABU","BK4585","LU0348723411.USD","LU0320765489.SGD","BK4533","SG9999014013.SGD","LU0170899867.USD","IHF","XLV","LU1983260115.SGD","SG9999014021.USD","LU0256863811.USD","BK4581","LU0070302665.USD","LU0208291251.USD","BK4154","LU0390134368.USD","HUM","LU1093756325.SGD","BK4566","BK4588","LU0417517546.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675477003","title":"FDA酝酿罕见病药物审批大改革！患者话语权提升 药企受监管路径有望更清晰","url":"https://stock-news.laohu8.com/highlight/detail?id=2675477003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675477003?lang=zh_cn&edition=full","pubTime":"2026-10-14 21:38","pubTimestamp":1791985107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AZNH","BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1196},{"period":"1month","weight":-0.1034},{"period":"3month","weight":-0.0697},{"period":"6month","weight":0.2314},{"period":"1year","weight":0.9169},{"period":"ytd","weight":0.4806}],"compareEarnings":[{"period":"1week","weight":-0.0115},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.029},{"period":"6month","weight":0.0855},{"period":"1year","weight":0.1456},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.020883},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.009536},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.135885},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.001739},{"month":5,"riseRate":0.545455,"avgChangeRate":0.013816},{"month":6,"riseRate":0.75,"avgChangeRate":0.158596},{"month":7,"riseRate":0.583333,"avgChangeRate":0.031304},{"month":8,"riseRate":0.666667,"avgChangeRate":0.021527},{"month":9,"riseRate":0.25,"avgChangeRate":-0.06835},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.052462},{"month":11,"riseRate":0.818182,"avgChangeRate":0.199161},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.032237}],"exchange":"ARCA","name":"三倍做多标普生物-Direxion","nameEN":"Direxion Daily S&P Biotech Bull 3x Shares"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三倍做多标普生物-Direxion,LABU,三倍做多标普生物-Direxion股票,三倍做多标普生物-Direxion股票老虎,三倍做多标普生物-Direxion股票老虎国际,三倍做多标普生物-Direxion行情,三倍做多标普生物-Direxion股票行情,三倍做多标普生物-Direxion股价,三倍做多标普生物-Direxion股市,三倍做多标普生物-Direxion股票价格,三倍做多标普生物-Direxion股票交易,三倍做多标普生物-Direxion股票购买,三倍做多标普生物-Direxion股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}